1
2
#OpenInnovation
3
4
News & Events
Congenica is Joint Winner of MIT Solve The Horizon Prize
September 21, 2021
Award recognizes the role of Congenica's AI in using data to help rare disease patients. Read more
mRNA Disruptor Goes Public in $1.5 Billion SPAC Deal
August 10, 2021
Messenger RNA has become the life sciences hero of the decade. Read more
InterVenn Biosciences Raises $201 Million
August 2, 2021
Series C financing for AI-driven Glycoproteomic Platform, Liquid-Biopsy development. Read more
5
#knowledgebase
6
7
News & Events
Congenica is Joint Winner of MIT Solve The Horizon Prize
September 21, 2021
Award recognizes the role of Congenica's AI in using data to help rare disease patients. Read more
mRNA Disruptor Goes Public in $1.5 Billion SPAC Deal
August 10, 2021
Messenger RNA has become the life sciences hero of the decade. Read more
InterVenn Biosciences Raises $201 Million
August 2, 2021
Series C financing for AI-driven Glycoproteomic Platform, Liquid-Biopsy development. Read more
8
Portfolio Highlights
#PharmaBiotech
11
Our View
10
Our Focus
12
#PRI
22
Medical Technologies
#Portfolio
14
16
Words from
the CEO
17
Portfolio Highlights
#PharmaBiotech
28
Pharmaceutical Biotech
#Portfolio
15
About Us
34
Biorenewables & Others
#Portfolio
19
WHAT'S TRENDING @ XERAYA
Congenica Joint Winner of MIT Solve The Horizon Prize
20
Our Team
21
23
Portfolio Highlights
#Biorenewables
30
Portfolio Highlights
#MedTech
25
26
ARE YOU
The Next
Big Thing?
Submit
A
Proposal
29
36
Career
#Xeraya
35
37
News & Events
Congenica is Joint Winner of MIT Solve The Horizon Prize
September 21, 2021
Award recognizes the role of Congenica's AI in using data to help rare disease patients. Read more
mRNA Disruptor Goes Public in $1.5 Billion SPAC Deal
August 10, 2021
Messenger RNA has become the life sciences hero of the decade. Read more
InterVenn Biosciences Raises $201 Million
August 2, 2021
Series C financing for AI-driven Glycoproteomic Platform, Liquid-Biopsy development. Read more
32
#agro
33
Portfolio Highlights
#Biorenewables
38
Portfolio Highlights
#MedTech
39
40
Contact Us
41
